TY - JOUR

T1 - Wirksamkeit Einer Verlängerten Arzneimittelapplikation zur Behandlung Mittelund Hochgradiger Klinischer Mastitiden Bei Milchkühen

AU - Krömker, Volker

AU - Paduch, Jan Hendrik

AU - Klocke, Doris

AU - Friedrich, Julia

AU - Zinke, Claudia

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Streptococcus uberis and Staphylococcus aureus are important mastitis pathogens in dairy cows in the entire world. Recent publications showed that an extended therapy can be more efficient in combating such intramammary infections. The objective of this study was to evaluate the effect of an extended intramammary therapy to treat moderate and severe mastitis cases in lactating dairy cows under field conditions in northern Germany. From December 2005 to August 2007, a total of 157 clinical mastitis cases on 10 farms in northern Germany were enrolled in the study and randomly assigned (blocked by parity and body temperature) to one of two treatment groups (intrammammary lincomycin/neomycin 1.5-d (ALK) or 5-d (ALL)). Clinical, microbiological and cytomicrobiological cure rates were evaluated. Treatments were initiated before culture results. Cows were observed and evaluated on d 1 to 6,19 and 26. Six cases in 157 (3,8%) resulted in a therapy change in between 48 h after mastitis detection. Overall, treatments were not significantly different to controls regarding clinical cure rate. However, when the microbiological cure rate was evaluated, differences were observed. ALL appeared to be the most efficient treatment (54/55 [98%] P < 0.01, ALK 30/40 [75%]). This was due to the fact that ALL yielded increased cure rates towards mastitis caused by Streptococcus uberis which was the most frequent micro organism after coliform infections. We conclude that in farms with Streptococcus uteris mastitis, the 5-d extended lincomycin/neomycin treatment regimen was significantly more efficient in microbiological cure than the standard 1.5-d treatment.

AB - Streptococcus uberis and Staphylococcus aureus are important mastitis pathogens in dairy cows in the entire world. Recent publications showed that an extended therapy can be more efficient in combating such intramammary infections. The objective of this study was to evaluate the effect of an extended intramammary therapy to treat moderate and severe mastitis cases in lactating dairy cows under field conditions in northern Germany. From December 2005 to August 2007, a total of 157 clinical mastitis cases on 10 farms in northern Germany were enrolled in the study and randomly assigned (blocked by parity and body temperature) to one of two treatment groups (intrammammary lincomycin/neomycin 1.5-d (ALK) or 5-d (ALL)). Clinical, microbiological and cytomicrobiological cure rates were evaluated. Treatments were initiated before culture results. Cows were observed and evaluated on d 1 to 6,19 and 26. Six cases in 157 (3,8%) resulted in a therapy change in between 48 h after mastitis detection. Overall, treatments were not significantly different to controls regarding clinical cure rate. However, when the microbiological cure rate was evaluated, differences were observed. ALL appeared to be the most efficient treatment (54/55 [98%] P < 0.01, ALK 30/40 [75%]). This was due to the fact that ALL yielded increased cure rates towards mastitis caused by Streptococcus uberis which was the most frequent micro organism after coliform infections. We conclude that in farms with Streptococcus uteris mastitis, the 5-d extended lincomycin/neomycin treatment regimen was significantly more efficient in microbiological cure than the standard 1.5-d treatment.

KW - Antibiotic therapy

KW - Bacteriological cure rates

KW - Clinical mastitis

KW - Extended therapy

KW - Lincomycin

KW - Neomycin

UR - http://www.scopus.com/inward/record.url?scp=77949804729&partnerID=8YFLogxK

U2 - 10.2376/0005-9366-123-147

DO - 10.2376/0005-9366-123-147

M3 - Tidsskriftartikel

AN - SCOPUS:77949804729

VL - 123

SP - 147

EP - 152

JO - Berliner und Muenchener Tieraerztliche Wochenschrift

JF - Berliner und Muenchener Tieraerztliche Wochenschrift

SN - 0005-9366

IS - 3-4

ER -